Bodybuilders and others who want to build muscle utilize Dindolyl Methane (or DIM). Recent studies have revealed that DIM could pose health hazards. DIM can cause liver damage when taken in excessive amounts. Kidney damage can also be a risk, and could lead to kidney failure. Many bodybuilders and athletes are worried about the long-term health risks that come with DIM.
Most people use a diindolylmethane supplement to improve the production of testosterone. It is known that testosterone functions as an androgen. This means that it can trigger hormonal changes within the tissues. DIM has been shown in studies to mimic the effects of testosterone, as well as other hormones. Certain manufacturers have added diindolylmethane (DIM) to their products to improve their popularity in male circles because men produce more testosterone than women do. Men will respond to products that mimic natural testosterone.
This is why many companies market DIM as a cancer-fighter. Although diindolylmethane can be effective in reducing the growth of tumors in laboratory animals it was given orally to the animals. To achieve the same result in humans, diindolylmethane would have to be consumed in large doses for a long period of time. The animals studied did not show any signs of cancer for many years. However, they all developed liver disease due to consuming excessive amounts of diindolylmethane. For a thorough glimpse of the way DIM works in the body, you should seek out a medical professional.
The only way to establish that DIM is effective in treating breast cancer is to conduct an experiment in which cells from healthy breast cells are exposed to high doses of diindolylmethane over an extended period of time. As with any chemical, there are both pros and cons associated with using it. Pros include the capability to mimic hormones. This allows you to make insulin that inhibits the growth of cancer cells. Cons include the fact that diindolylmethane also produces potentially damaging chemicals known as DMSO. Learn more about diindolylmethane dim now.
One of the most popular claims made about diindolylmethane treatment for various health problems is that it can act as a natural, antibacterial, anti-fungal and anti-cancer drug. The National Institute of Health, in their exhaustive review of the supporting evidence concluded that there was no evidence to support these claims. According to the Institute of Chemical Technology there were no studies which supported this assertion. In a thorough study of the safety profile of the firestone, the Institute of Chemical Safety concluded that the evidence provided by pharmaceutical companies about the human benefits of diindolylmethane was not reliable.
Van der Goes, et. and. published their findings in a May 2021 issue of the Journal of Toxicology and Environmental Health. Van der Goes, and., highlighted the potential risks of diindolylmethane, which includes allergic reactions to the skin asthma attacks as along with headaches, dizziness and respiratory issues. They also stated that the recommended daily allowance for this chemical is 0.2 milligrams, or about one 10th of a teaspoon. It isn’t clear what the concentration is when compounded with other compounds. This substance isn’t safe because it has not been thoroughly examined.
The view abstract shows that the use of diindolylmethane for cancer treatment is based on the principle that intracellular inhibition of pyruvate metabolism via flavenoids can be slowed down and prevents accumulation of oxalates and pyruvate metabolites in the renal tubule cells. The drug metabiplicate toxicology studies have not shown that this chemical is able to cause overdose. In June 1996, the Food and Drug Administration approved this drug as a prescribed drug. According to the FDA the manufacturer of firestone Tincture is currently conducting two major tests in Europe and the United States.
The abstract of the view also indicates that diindolylmethane’s use in the treatment of cancer is based on the idea of inhibiting intracellular inhibition via flavenoids of pyruvate metabolism , and thus stopping the accumulation of adenine and oxalates within the renal tubule cells. Metabiplicate toxicology studies on the drug have not proven that this chemical is able to cause overdose. In June 1996, the Food and Drug Administration approved this drug as a prescribed drug. According to the FDA the manufacturer of firestone tincture is in process of completing two major trials – one in Europe and one in the United States. According to the FDA the company that makes firestone tincture is in process of finishing two major trials in Europe and one in the United States.